BBOT (BridgeBio Oncology Therapeutics) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
Company Details
- Employees
- 69
- Address
- 1 Corporate Drive, South San Francisco,ca 94080,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.bridgebiooncology.com
- HQ
- South San Francisco, CA
Bbot Questions
Bbot's website is http://www.bridgebiooncology.com
Bbot's LinkedIn profile is https://www.linkedin.com/company/bbotherapeutics
Bbot has
69 employees.
View email and phone details for 69
employees at Bbot.
Bbot's industry is
Biotechnology Research
Bbot's top competitors are
Bridgebio,
Amgen,
Repertoire Immune Medicines,
Crinetics Pharmaceuticals,
Beone Medicines,
Enlaza Therapeutics,
Gondolabio,
Avidity Biosciences, Inc.,
Revolution Medicines,
Apogee Therapeutics.
Bbot's categories are Biotechnology Research
